A phase 2 pivotal trial of AB-SA01 to treat patients with Staphylococcal-infections

Trial Profile

A phase 2 pivotal trial of AB-SA01 to treat patients with Staphylococcal-infections

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs AB SA01 (Primary)
  • Indications Staphylococcal infections
  • Focus Registrational; Therapeutic Use
  • Sponsors AmpliPhi Biosciences Corporation
  • Most Recent Events

    • 21 Dec 2017 New trial record
    • 14 Dec 2017 According to an AmpliPhi Biosciences media release, company plans to initiate the clinical trial in second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top